An Open-label Study of the Effect of First Line Treatment With Xeloda in Combination With Chemotherapy on Safety and Treatment Response in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-based Regimen

Trial Profile

An Open-label Study of the Effect of First Line Treatment With Xeloda in Combination With Chemotherapy on Safety and Treatment Response in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-based Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 25 Mar 2010 Planned number of patients changed from 195 to 157 as reported by as reported by Roche record.
    • 23 Feb 2010 Planned number of patients changed from 157 to 195 as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Planned number of patients changed from 154 to 157, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top